1. Patel A, Agarwal R, Rudramurthy SM, Shevkani M, Xess I, Sharma R, et al. Multicenter epidemiologic study of coronavirus disease-associated mucormycosis, India. Emerg Infect Dis. 2021;27(9):2349–59.
2. Soman R, Sunavala A. Post COVID-19 mucormycosis-from the frying pan into the fire. J Assoc Physicians India. 2021;69(1):13–4.
3. Soman R, Sunavala A. Post COVID-19 mucormycosis in the second wave-realities, uncertainties and myths. J Assoc Physicians India. 2021;69(7):11–2.
4. Rex JH, Stevens DA. Drugs active against fungi, pneumocystis, and microsporidia. In: Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. WB Saunders; 2015. p. 479–94.
5. Cavassin FB, Baú-Carneiro JL, Vilas-Boas RR, et al. Sixty years of amphotericin B: an overview of the main antifungal agent used to treat invasive fungal infections. Infect Dis Ther. 2021;10:115–47.